文献速递临床试验与 GCP流行病学与生物统计

缺血性卒中合并心房颤动抗凝最佳时机协作研究:随机对照试验的系统综述与前瞻性个体参与者数据Meta分析(CATALYST)

Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST).
PubMed 文献 · Lancet · 2025-06-23

该系统综述与个体参与者数据Meta分析检索了截至2025年3月16日的随机对照试验,纳入4项试验共5441例急性缺血性卒中合并心房颤动患者,比较早期(≤4天)与后期(≥5天)启动直接口服抗凝药的效果。主要复合结局在早期组57/2683(2.1%) vs 后期组83/2746(3.0%),OR 0.70(95%CI 0.50-0.98,p=0.039)。作者认为这些发现支持在临床实践中早期启动DOAC。

要点

  • 早期(≤4天)启动DOAC较后期(≥5天)降低30天主要复合结局风险,OR 0.70(95%CI 0.50-0.98)。
  • 早期DOAC降低复发性缺血性卒中风险,45/2683(1.7%) vs 70/2746(2.6%),OR 0.66(95%CI 0.45-0.96)。
  • 早期启动未增加症状性颅内出血,10/2683(0.4%) vs 10/2746(0.4%),OR 1.02(95%CI 0.43-2.46)。

核心结论

  • 对于急性缺血性卒中合并心房颤动患者,早期(4天内)启动DOAC降低了30天内复发性缺血性卒中、症状性颅内出血或未分类卒中的复合结局风险。
  • 作者认为这些发现支持在临床实践中早期启动DOAC。

研究设计与样本

  • 系统综述与前瞻性个体参与者数据Meta分析,检索PubMed、Cochrane对照试验中心注册库和Embase从建库至2025年3月16日发表的随机对照试验。
  • 纳入标准为预注册、随机、评估临床结局、纳入急性缺血性卒中合并心房颤动并分配至早期(≤4天)或后期(≥5天)启动批准剂量DOAC的试验。
  • 共识别4项合格试验:TIMING(NCT02961348)、ELAN(NCT03148457)、OPTIMAS(NCT03759938)和START(NCT03021928)。
  • 排除选择不共享数据或未随机分配至4天内或第5天及以后启动DOAC的参与者后,纳入5441例参与者(平均年龄77.7岁[SD 10.0],2472例[45.4%]女性,美国国立卫生研究院卒中量表评分中位数5[IQR 3-10])。
  • 获得5429例参与者的主要结局数据;采用广义线性混合效应模型进行一步法个体患者数据Meta分析,考虑试验间差异,以OR和95%CI呈现治疗效果。

主要发现

  • 主要结局(随机化后30天内复发性缺血性卒中、症状性颅内出血或未分类卒中的复合结局)在早期DOAC组57/2683(2.1%) vs 后期DOAC组83/2746(3.0%),OR 0.70(95%CI 0.50-0.98,p=0.039)。
  • 复发性缺血性卒中在早期DOAC组45/2683(1.7%) vs 后期DOAC组70/2746(2.6%),OR 0.66(95%CI 0.45-0.96,p=0.029)。
  • 症状性颅内出血在早期DOAC组10/2683(0.4%) vs 后期DOAC组10/2746(0.4%),OR 1.02(95%CI 0.43-2.46,p=0.96),无证据表明早期启动增加症状性颅内出血。

关键数值与推荐

  • 早期DOAC定义为缺血性卒中发病后≤4天启动,后期定义为≥5天启动。
  • 主要结局为随机化后30天内复发性缺血性卒中、症状性颅内出血或未分类卒中的复合结局。
  • 次要结局包括30天和90天内主要复合结局的各个组成部分。

临床怎么用

  • 作者认为这些发现支持在临床实践中早期启动DOAC。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal timing of oral anticoagulation for prevention of early ischaemic stroke recurrence in people with acute ischaemic stroke and atrial fibrillation remains uncertain. We aimed to estimate the effects of starting a direct oral anticoagulant (DOAC) early (≤4 days) versus later (≥5 days) after onset of ischaemic stroke. METHODS: For this systematic review and meta-analysis we searched the electronic databases PubMed, Cochrane Central Register of Controlled Trials, and Embase for randomised controlled trials published from inception until March 16, 2025. We included clinical trials if they were pre-registered, randomised, investigated clinical outcomes, and included participants with acute ischaemic stroke and atrial fibrillation who were assigned to either early or later initiation (≤4 days vs ≥5 days) of a DOAC in approved doses. The primary outcome was a composite of recurrent ischaemic stroke, symptomatic intracerebral haemorrhage, or unclassified stroke within 30 days of randomisation. Secondary outcomes included components of the primary composite within 30 days and 90 days. We did a one-stage individual patient data meta-analysis with the use of a generalised linear mixed-effects model, accounting for between-trial differences, to generate treatment effects, which are presented as odds ratios (ORs) and 95% CIs. This study is registered with PROSPERO, CRD42024522634. FINDINGS: We identified four eligible trials: TIMING (NCT02961348), ELAN (NCT03148457), OPTIMAS (NCT03759938), and START (NCT03021928). After excluding participants who opted out of data sharing or were not randomly assigned to DOAC initiation within 4 days or at day 5 or later, we included 5441 participants (mean age 77·7 years [SD 10·0], 2472 [45·4%] women, median National Institutes of Health Stroke Scale 5 [IQR 3-10]) in the individual patient data meta-analysis. We obtained primary outcome data for 5429 participants. The primary outcome occurred in 57 (2·1%) of 2683 participants who started DOAC early versus 83 (3·0%) of 2746 participants who started later (OR 0·70, 95% CI 0·50-0·98, p=0·039). Early DOAC reduced the risk of recurrent ischaemic stroke (45 [1·7%] of 2683 vs 70 [2·6%] of 2746, OR 0·66, 0·45-0·96, p=0·029). There was no evidence of an increase in symptomatic intracerebral haemorrhage with early DOAC initiation (10 [0·4%] of 2683 vs 10 [0·4%] of 2746, OR 1·02, 0·43-2·46, p=0·96). INTERPRETATION: For people with acute ischaemic stroke and atrial fibrillation, early DOAC initiation (within 4 days) reduced the risk of the composite outcome of recurrent ischaemic stroke, symptomatic intracerebral haemorrhage, or unclassified stroke within 30 days. These findings support early DOAC initiation in clinical practice. FUNDING: The CATALYST collaboration was facilitated by a British Heart Foundation grant for OPTIMAS (grant reference number CS/17/6/33361), with support from researchers at the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and a Swiss National Science Foundation grant for ELAN (32003B_197009; 32003B_169975).

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Dehbi HM, Fischer U, Åsberg S, et al. Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST). Lancet. 2025. PMID: 40570866. doi:10.1016/S0140-6736(25)00439-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。